Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits

E. H. Herman, V. J. Ferrans, W. Jordan, Bach Ardalan

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

To determine whether ICRF-187 (NSC-169780) would alter chronic daunorubicin (NSC-82151) cardiac toxicity, male New Zealand rabbits were given 3.2 mg/kg of daunorubicin iv alone or 30 minutes after 12.5 or 25.0 mg/kg of ICRF-187 ip at 3-week intervals. Control rabbits received either saline iv or ICRF-187 (12.5 or 25.0 mg/kg) ip on the same schedule. Three weeks after the fifth injection, the animals were sacrificed. The frequency and extent of cellular alterations were graded on a scale of 0 to 4. Lesions consisting mainly of vacuolization and myofibrillar loss were noted in the hearts of all 12 rabbits given daunorubicin alone. The severity ranged from 1 to 3 (average 1.8). In contrast, no abnormalities were noted in one of five (12.5 mg/kg) and three of seven (25.0 mg/kg) ICRF-treated rabbits. The remaining eight hearts from both pretreatment groups displayed minimal alterations ranging from 0.5 to 1.0 (average 0.9). Thus, concurrent administration of the antineoplastic agent ICRF-187 may offer a means of reducing chronic daunorubicin cardiac toxicity.

Original languageEnglish
Pages (from-to)85-97
Number of pages13
JournalResearch Communications in Chemical Pathology and Pharmacology
Volume31
Issue number1
StatePublished - Jan 1 1981
Externally publishedYes

Fingerprint

Dexrazoxane
Daunorubicin
Rabbits
Toxicity
Antineoplastic Agents
Animals
Appointments and Schedules
Cardiotoxicity
Injections

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. / Herman, E. H.; Ferrans, V. J.; Jordan, W.; Ardalan, Bach.

In: Research Communications in Chemical Pathology and Pharmacology, Vol. 31, No. 1, 01.01.1981, p. 85-97.

Research output: Contribution to journalArticle

@article{abb3cfdd0f0149a2a84d8ac6dd0f9072,
title = "Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits",
abstract = "To determine whether ICRF-187 (NSC-169780) would alter chronic daunorubicin (NSC-82151) cardiac toxicity, male New Zealand rabbits were given 3.2 mg/kg of daunorubicin iv alone or 30 minutes after 12.5 or 25.0 mg/kg of ICRF-187 ip at 3-week intervals. Control rabbits received either saline iv or ICRF-187 (12.5 or 25.0 mg/kg) ip on the same schedule. Three weeks after the fifth injection, the animals were sacrificed. The frequency and extent of cellular alterations were graded on a scale of 0 to 4. Lesions consisting mainly of vacuolization and myofibrillar loss were noted in the hearts of all 12 rabbits given daunorubicin alone. The severity ranged from 1 to 3 (average 1.8). In contrast, no abnormalities were noted in one of five (12.5 mg/kg) and three of seven (25.0 mg/kg) ICRF-treated rabbits. The remaining eight hearts from both pretreatment groups displayed minimal alterations ranging from 0.5 to 1.0 (average 0.9). Thus, concurrent administration of the antineoplastic agent ICRF-187 may offer a means of reducing chronic daunorubicin cardiac toxicity.",
author = "Herman, {E. H.} and Ferrans, {V. J.} and W. Jordan and Bach Ardalan",
year = "1981",
month = "1",
day = "1",
language = "English",
volume = "31",
pages = "85--97",
journal = "Research Communications in Molecular Pathology and Pharmacology",
issn = "0034-5164",
publisher = "PJD Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits

AU - Herman, E. H.

AU - Ferrans, V. J.

AU - Jordan, W.

AU - Ardalan, Bach

PY - 1981/1/1

Y1 - 1981/1/1

N2 - To determine whether ICRF-187 (NSC-169780) would alter chronic daunorubicin (NSC-82151) cardiac toxicity, male New Zealand rabbits were given 3.2 mg/kg of daunorubicin iv alone or 30 minutes after 12.5 or 25.0 mg/kg of ICRF-187 ip at 3-week intervals. Control rabbits received either saline iv or ICRF-187 (12.5 or 25.0 mg/kg) ip on the same schedule. Three weeks after the fifth injection, the animals were sacrificed. The frequency and extent of cellular alterations were graded on a scale of 0 to 4. Lesions consisting mainly of vacuolization and myofibrillar loss were noted in the hearts of all 12 rabbits given daunorubicin alone. The severity ranged from 1 to 3 (average 1.8). In contrast, no abnormalities were noted in one of five (12.5 mg/kg) and three of seven (25.0 mg/kg) ICRF-treated rabbits. The remaining eight hearts from both pretreatment groups displayed minimal alterations ranging from 0.5 to 1.0 (average 0.9). Thus, concurrent administration of the antineoplastic agent ICRF-187 may offer a means of reducing chronic daunorubicin cardiac toxicity.

AB - To determine whether ICRF-187 (NSC-169780) would alter chronic daunorubicin (NSC-82151) cardiac toxicity, male New Zealand rabbits were given 3.2 mg/kg of daunorubicin iv alone or 30 minutes after 12.5 or 25.0 mg/kg of ICRF-187 ip at 3-week intervals. Control rabbits received either saline iv or ICRF-187 (12.5 or 25.0 mg/kg) ip on the same schedule. Three weeks after the fifth injection, the animals were sacrificed. The frequency and extent of cellular alterations were graded on a scale of 0 to 4. Lesions consisting mainly of vacuolization and myofibrillar loss were noted in the hearts of all 12 rabbits given daunorubicin alone. The severity ranged from 1 to 3 (average 1.8). In contrast, no abnormalities were noted in one of five (12.5 mg/kg) and three of seven (25.0 mg/kg) ICRF-treated rabbits. The remaining eight hearts from both pretreatment groups displayed minimal alterations ranging from 0.5 to 1.0 (average 0.9). Thus, concurrent administration of the antineoplastic agent ICRF-187 may offer a means of reducing chronic daunorubicin cardiac toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0019352522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019352522&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 85

EP - 97

JO - Research Communications in Molecular Pathology and Pharmacology

JF - Research Communications in Molecular Pathology and Pharmacology

SN - 0034-5164

IS - 1

ER -